Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 8Phase 1 5Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Lung Neoplasms 3Stomach Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms, Male 2Uterine Neoplasms 1Thrombosis 1Peritoneal Neoplasms 1Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer 1Pancreatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1NSCLC 1Inflammatory Breast Neoplasms 1Infections 1Hypopharyngeal Neoplasms 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Drug-Related Side Effects and Adverse Reactions 1Carcinogenesis 1Breast Neoplasm Female 1Breast Diseases 1Amenorrhea 1Adenocarcinoma 1

Interventions

Radiotherapy 8camrelizumab 3Drug Therapy 3Cisplatin 3sintilimab 2Paclitaxel 2Neoadjuvant Therapy 2toripalimab 1tislelizumab 1pembrolizumab 1durvalumab 1anlotinib 1Surgical Procedures, Operative 1Radiofrequency Ablation 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Observation 1Narrow Band Imaging 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Immune Checkpoint Inhibitors 1Gene Expression Profiling 1Fluorouracil 1Fluorodeoxyglucose F18 1Esophagectomy 1Endoscopy, Digestive System 1Docetaxel 1Consolidation Chemotherapy 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Esophageal Squamous Cell Carcinoma × Docetaxel × Clear all
NCT01551589 2017-07-26

Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer

The Second People's Hospital of Sichuan

Phase NA Completed
220 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡